A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Signed written informed consent form voluntarily. * Histologically or cytologically documented hepatocellular carcinoma. * BCLC stage C, and non-resectable BCLC stage B . * At least one measurable lesion according to RECIST criteria. * ECOG of 0 or 1. * Adequate organ function. * Estimated life expectancy of ≥3 months. * For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent. Exclusion Criteria: * Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc. * History of hepatic encephalopathy or liver transplantation. * Clinical significance of hydrothorax, ascites or pericardial effusion. * Central nervous system metastases and/or carcinomatous meningitis. * Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy. * Occurred arteriovenous thromboembolic events within 6 months before the first administration. * Tumor volume \> 50% liver volume; portal vein tumor thrombus or inferior vena cava tumor thrombus. * Inadequately controlled arterial hypertension. * Attack of symptomatic congestive heart failure (LVEF\<50%); History of congenital long QT syndrome. * Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease. * Severe infections. * Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy, * Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs. * Unable to receive an enhanced CT or MRI scan of the liver.